Home > Neurology > EAN 2020 > Parkinson's Disease > Directional DBS superior to omnidirectional DBS

Directional DBS superior to omnidirectional DBS

Presented By
Prof. Alfons Schnitzler, Heinrich-Heine-University Düsseldorf, Germany
Conference
EAN 2020
Trial
PROGRESS
Directional deep brain stimulation (DBS) in Parkinson’s disease (PD) yielded a wider therapeutic window and a lower therapeutic current strength than conventional omnidirectional DBS in the prospective blinded crossover PROGRESS study [1]. Directional DBS was also preferred by subjects. Patients receiving subthalamic nucleus DBS for PD received omnidirectional stimulation for 3 months, followed by directional stimulation for another 3 months. Superiority of directional stimulation required a wider therapeutic window in >60% of patients after 3 months (primary endpoint). For non-inferiority of directional stimulation, this percentage was set at 40% (secondary endpoint). A directional DBS system was implanted in 234 subjects, without intracranial haemorrhages or infections occurring. There were 13 serious adverse...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on